September 22, 2023 Aaron Gerds, MD, MS: The NCCN [National Comprehensive Cancer Network] guidelines for polycythemia vera and the other MPNs [myeloproliferative neoplasms] are updated regularly. So certainly there’s a large effort to annually update them, where we go over the entire sets of guidelines to update and refine them. But as new developments come along, […]
Sep 15, 2023 Ariana Pelosci The News The FDA has approved momelotinib (Ojjaara) for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary and secondary myelofibrosis, who are experiencing anemia, according to a press release from GSK.1 The approval was based on results from the phase 3 MOMENTUM trial (NCT04173494), which was previously […]
Sep 6, 2023 Daniel H. Foley, MD Kristen Pettit, MD Our understanding of pathophysiology driving Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) has evolved considerably over the past decade. As a result, the therapeutic landscape is shifting toward a goal of meaningful disease modification. For patients with essential thrombocytosis (ET), the immediate goals remain thrombosis risk reduction […]
Sep 8, 2023 Tony Berberabe, MPH Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms (MPN AP or MPN BP) requires consideration of a patient’s ability to tolerate intensive induction as initial therapy, their eligibility for allogeneic stem cell transplant (ASCT), and whether prior cytoreduction is necessary, according to a presentation […]
Sep 8, 2023 Brielle Benyon Anemia is a common and potentially dangerous condition that can occur in patients with myelofibrosis, a type of myeloproliferative neoplasm. While anemia is a blanket term that describes low hemoglobin levels, myelofibrosis-related anemia behaves quite differently than anemia in patients with a blood cancer diagnosis, explained Sharon Bledsoe. Bledsoe, a […]
Sep 6, 2023 Daniel H. Foley, MD Kristen Pettit, MD The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification. Our understanding of pathophysiology driving Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) has evolved considerably over the past decade. As a result, the therapeutic landscape is shifting toward a goal of meaningful […]
Sep 7, 2023 Targeted Oncology Staff During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed elements to diagnosing myelofibrosis and how to approach risk stratification before treatment. KOMROKJI: MF could be either primary de novo or coming from secondary from essential thrombocythemia [ET] or polycythemia vera [PT]. [Concerning] the major criteria listed [by the […]
Sep 7, 2023 Russ Conroy Mohammad Bakri Hammami, MD, highlights a need to address socio-racial disparities among Black and non-Black patients with primary myelofibrosis to ensure that everyone receives high-quality treatment. Investigators retrospectively reviewed socio-racial characteristics as potential determinants of survival in patients with primary myelofibrosis and compared the dataset with single-center outcomes of patients […]
Sep 6, 2023 Megan Hollasch A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with […]
Sep 6, 2023 Daniel H. Foley, MD Kristen Pettit, MD The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification. Our understanding of pathophysiology driving Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) has evolved considerably over the past decade. As a result, the therapeutic landscape is shifting toward a goal of meaningful […]